9 completed, 6 terminated, 2 active not recruiting. 13 Phase 1, 6 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Terminated 4, Active not recruiting 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
Follow uproleselan: new trials by email Literature Review of uproleselan trials Research Report on uproleselan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Uproleselan, Fludarabine, Clofarabine - Acute Myeloid Leukemia, Pediatric Cancer | Phase 1 | Terminated | Malika Kapadia | 1 | 2022-10-06 | 2024-08-19 |
| Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Uproleselan, Placebo - Relapsed/Refractory AML | Phase 3 | Terminated | Apollomics Inc. | 140 | 2021-11-17 | 2025-06-27 |
| Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia Uproleselan - COVID-19 Pneumonia | Phase 1 / Phase 2 | Terminated | Lena Napolitano, MD | 6 | 2021-11-12 | 2023-07-10 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Terminated | Brian Jonas | 16 | 2021-07-02 | 2026-02-23 |
| Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia Cladribine, Cytarabine, Uproleselan - Secondary Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2021-06-11 | 2026-06-05 |
| Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) Uproleselan, Placebo, Melphalan - Multiple Myeloma | Phase 2 | Completed | Washington University School of Medicine | 51 | 2021-05-05 | 2023-12-15 |
| Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Uproleselan - Relapsed/Refractory AML | Phase 1 | Completed | Apollomics Inc. | 12 | 2021-02-24 | 2025-06-27 |
| Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2019-03-28 | 2026-01-21 |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Uproleselan, Placebo - Acute Myeloid Leukemia | Phase 3 | Terminated | GlycoMimetics Incorporated | 388 | 2018-10-15 | 2024-07-29 |
| A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV) Uproleselan - Healthy Subjects | Phase 1 | Completed | GlycoMimetics Incorporated | 5 | 2018-08-14 | 2019-05-14 |
| Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT) GMI-1271, Enoxaparin Sodium (Lovenox®) - Deep Venous Thrombosis | Phase 1 / Phase 2 | Terminated | GlycoMimetics Incorporated | 2 | 2016-07-01 | 2019-06-14 |
| A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma GMI-1271 - Multiple Myeloma | Phase 1 | Completed | GlycoMimetics Incorporated | 10 | 2016-06-01 | 2019-07-10 |
| A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects GMI-1271, Filgrastim, Placebo Injection - Healthy Volunteers | Phase 1 | Completed | GlycoMimetics Incorporated | 54 | 2015-11-01 | 2018-02-27 |
| Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML GMI-1271, Mitoxantrone, Etoposide - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Completed | GlycoMimetics Incorporated | 91 | 2015-03-01 | 2019-05-17 |
| Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®) - Healthy Volunteers | Phase 1 | Completed | GlycoMimetics Incorporated | 32 | 2014-10-01 | 2018-02-27 |
| Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers GMI-1271, Placebo - Healthy Adult Subjects | Phase 1 | Completed | GlycoMimetics Incorporated | 28 | 2014-06-01 | 2018-02-27 |
Leukemia, Myeloid, Acute (8) · Multiple Myeloma (2) · Leukemia, Biphenotypic, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Venous Thrombosis (1)
GlycoMimetics Incorporated (8) · Apollomics Inc. (2) · National Cancer Institute (NCI) (2) · Brian Jonas (1) · Lena Napolitano, MD (1) · M.D. Anderson Cancer Center (1) · Malika Kapadia (1) · Washington University School of Medicine (1)
United States (13) · Ireland (3) · United Kingdom (3) · Australia (2) · China (2) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1)
Jianxiang Wang, PhD (2) · Suman Sood, MD (2) · Barbara Cook, MD (1) · Brian A Jonas (1) · Daniel DeAngelo, MD, PhD (1) · Daniel J DeAngelo, MD, PhD (1) · Geoffrey L Uy (1) · Keith Stockerl-Goldstein, M.D. (1) · Laura Sterling, MD (1) · Lena Napolitano, MD (1) · Malika Kapadia, MD (1) · Maria Luisa Sulis (1) · Michael O'Dwyer, MD (1) · Nand Singh, MD,DPM,MFPM (1) · Tapan M Kadia (1)
P30CA093373 (1), U10CA180821 (1), UM1CA228823 (1)